Literature DB >> 22882224

The utility of diagnostic biopsy specimens for predictive molecular testing in colorectal cancer.

Wakkas Fadhil1, Salih Ibrahem, Rashmi Seth, Ghada AbuAli, Krishna Ragunath, Philip Kaye, Mohammad Ilyas.   

Abstract

AIMS: If stratified medicine is to be applied in the neoadjuvant setting, predictive testing will have to be undertaken on preoperative diagnostic biopsy specimens. The aim of this study was to evaluate whether a diagnostic biopsy was adequately representative of the main tumour in colorectal cancer. METHODS AND
RESULTS: Thirty cases of paired biopsy and subsequent resection specimens were randomly selected. Samples were screened for mutation in KRAS (codons 12/13, 61, and 146), BRAF (codon 600 and exon 11), PIK3CA (exons 1, 9, and 20), TP53 (exons 5-8), and microsatellite instability, using the quick multiplex consensus or standard polymerase chain reaction (PCR) protocols followed by high-resolution melting analysis. A total of 570 paired PCR tests were performed for mutation detection, and identical results were obtained in both biopsy and resection specimens in 569 tests (>99% concordance). Four cases (13%) showed microsatellite instability, and, in all four cases, instability was seen at identical mononucleotide markers in both biopsy and matched resection specimens.
CONCLUSIONS: This is the first study to show that diagnostic biopsy specimens, even though they are a tiny sample of the tumour, are sufficiently representative for use in predictive testing for early driver mutations in colorectal cancer.
© 2012 Blackwell Publishing Limited.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22882224     DOI: 10.1111/j.1365-2559.2012.04321.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  9 in total

1.  IMP3 expression in biopsy specimens of colorectal cancer predicts lymph node metastasis and TNM stage.

Authors:  Qingzhu Wei; Xiaoping Huang; Bo Fu; Jianghuan Liu; Ling Zhong; Qiao Yang; Tong Zhao
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

2.  DNA content analysis of colorectal cancer defines a distinct 'microsatellite and chromosome stable' group but does not predict response to radiotherapy.

Authors:  Wakkas Fadhil; Karin Kindle; Darryl Jackson; Abed Zaitoun; Nina Lane; Adrian Robins; Mohammad Ilyas
Journal:  Int J Exp Pathol       Date:  2014-02       Impact factor: 1.925

Review 3.  Practical opportunities to improve early detection and prevention of colorectal cancer (CRC) in members of high-risk families.

Authors:  S G Patel; J T Lowery; D Gatof; D J Ahnen
Journal:  Dig Dis Sci       Date:  2015-02-20       Impact factor: 3.199

4.  Targeted Next-Generation Sequencing Validates the Use of Diagnostic Biopsies as a Suitable Alternative to Resection Material for Mutation Screening in Colorectal Cancer.

Authors:  Hersh A Ham-Karim; Henry Okuchukwu Ebili; Kirsty Manger; Wakkas Fadhil; Narmeen S Ahmad; Susan D Richman; Mohammad Ilyas
Journal:  Mol Diagn Ther       Date:  2019-06       Impact factor: 4.074

5.  Comparison of universal screening in major lynch-associated tumors: a systematic review of literature.

Authors:  George Kunnackal John; Vipin Das Villgran; Christine Caufield-Noll; Francis M Giardiello
Journal:  Fam Cancer       Date:  2021-01-11       Impact factor: 2.375

6.  RAS mutations vary between lesions in synchronous primary colorectal cancer: testing only one lesion is not sufficient to guide anti-EGFR treatment decisions.

Authors:  Mariana Petaccia de Macedo; Fernanda Machado de Melo; Júlia da Silva Ribeiro; Celso Abdon Lopes de Mello; Maria Dirlei Ferreira de Souza Begnami; Fernando Augusto Soares; Dirce Maria Carraro; Isabela Werneck da Cunha
Journal:  Oncoscience       Date:  2015-02-09

7.  Genetic and Epigenetic Intra-tumour Heterogeneity in Colorectal Cancer.

Authors:  Huw Geraint Jones; Gareth Jenkins; Namor Williams; Paul Griffiths; Phil Chambers; John Beynon; Dean Harris
Journal:  World J Surg       Date:  2017-05       Impact factor: 3.352

8.  Worldwide variation in lynch syndrome screening: case for universal screening in low colorectal cancer prevalence areas.

Authors:  George Kunnackal John; Vipin Das Villgran; Christine Caufield-Noll; Francis Giardiello
Journal:  Fam Cancer       Date:  2020-09-11       Impact factor: 2.375

9.  Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review.

Authors:  Yu Imamura; Paul Lochhead; Mai Yamauchi; Aya Kuchiba; Zhi Rong Qian; Xiaoyun Liao; Reiko Nishihara; Seungyoun Jung; Kana Wu; Katsuhiko Nosho; Yaoyu E Wang; Shouyong Peng; Adam J Bass; Kevin M Haigis; Jeffrey A Meyerhardt; Andrew T Chan; Charles S Fuchs; Shuji Ogino
Journal:  Mol Cancer       Date:  2014-05-31       Impact factor: 27.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.